Teleflex Incorporated (TFX)
| Market Cap | 6.00B |
| Revenue (ttm) | 1.99B |
| Net Income (ttm) | -905.64M |
| Shares Out | 44.27M |
| EPS (ttm) | -20.25 |
| PE Ratio | n/a |
| Forward PE | 20.16 |
| Dividend | $1.36 (1.00%) |
| Ex-Dividend Date | Mar 6, 2026 |
| Volume | 795,355 |
| Open | 133.99 |
| Previous Close | 135.07 |
| Day's Range | 133.08 - 135.91 |
| 52-Week Range | 100.18 - 139.67 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 138.75 (+2.38%) |
| Earnings Date | May 7, 2026 |
About TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and col... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TFX stock is "Buy." The 12-month stock price target is $138.75, which is an increase of 2.38% from the latest price.
News
Teleflex Announces First Quarter 2026 Earnings Conference Call Information
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on ...
CVC, GTCR weigh taking Teleflex private, Bloomberg News reports
Private equity firms CVC and GTCR are weighing a takeover of medical equipment provider Teleflex , Bloomberg News reported on Tuesday, citing people familiar with the matter.
Teleflex Incorporated Investigated by the Portnoy Law Firm
LOS ANGELES, April 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Teleflex Incorporated , (“ Teleflex " or the "Company") ( NYSE : TFX) investors that the firm has initiated an investigati...
Teleflex Announces Governance Updates
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced several Board and governance updates, including the nomination of Mich...
Irenic Comments on Teleflex's Announcement That It Is Open to Strategic Alternatives
NEW YORK--(BUSINESS WIRE)--Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX) with 2% ownership, today issued the followi...
Teleflex Reiterates Commitment to Value Maximizing Strategies and Strong Execution
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today issued the following statement in response to the press release issued by Irenic...
Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors
NEW YORK--(BUSINESS WIRE)--Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX) with 2% ownership, today sent the below let...
o9 Announces Teleflex™ Global Go-Live for Integrated Demand and Supply Planning
DALLAS--(BUSINESS WIRE)--o9, a leading enterprise AI software platform provider for transforming planning and decision-making, today announced that Teleflex Incorporated (NYSE: TFX), a leading global ...
Teleflex Earnings Call Transcript: Q4 2025
Year-end results show 8.7% EPS growth and strong segment performance, with 2026 guidance reflecting a transition year due to divestitures and stranded costs. Significant EPS and margin improvements are expected in 2027 as cost offsets, share repurchases, and debt reduction take effect.
Teleflex Announces Quarterly Dividend
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. Th...
Teleflex Reports 2025 Financial Results and Full Year 2026 Outlook
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the year ended December 31, 2025. Full year 2025 continuing operations financial su...
Teleflex Announces Fourth Quarter 2025 Earnings Conference Call Information
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern Ti...
Teleflex Announces Leadership Transition
Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Reve...
Montagu and Kohlberg to Acquire Teleflex Medical OEM in a Carve-out Transaction
NEW YORK--(BUSINESS WIRE)--Montagu and Kohlberg, two leading middle-market private equity firms, today announced that they have entered into a definitive agreement to acquire Teleflex Medical OEM (the...
Teleflex to sell three of its businesses for $2.03 billion
Medical device maker Teleflex said on Tuesday it will sell three of its business units for a total of $2.03 billion in cash.
Teleflex Announces Sale of Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion
Board of Directors authorizes new $1 billion share repurchase program Board of Directors authorizes new $1 billion share repurchase program
Teleflex Transcript: Jefferies London Healthcare Conference 2025
Leadership detailed the strategic separation into RemainCo and NewCo, prioritizing a sale of NewCo due to strong interest. RemainCo will focus on acute care with a simplified structure and growth driven by BIOTRONIK integration and innovation. Margin expansion, tariff mitigation, and balanced capital allocation are key priorities.
Teleflex Transcript: Investor Update
The acquisition of the Vascular Intervention business enhances the interventional portfolio with complementary technologies, driving above-market growth and expanding global reach. Key products like Orsiro Mission, Pantera Lux, and Freesolve RMS position the business for leadership in complex PCI and lifetime disease management, supported by robust clinical evidence and innovation.
Teleflex to Present at the Jefferies Global Healthcare Conference in London
WAYNE, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) is scheduled to speak at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 202...
These Analysts Cut Their Forecasts On Teleflex Following Q3 Results
Teleflex Incorporated (NYSE:TFX) reported better-than-expected earnings for the third quarter on Thursday.
Teleflex Earnings Call Transcript: Q3 2025
Separation into RemainCo and NewCo is progressing, with a sale of NewCo prioritized due to strong buyer interest. Q3 revenue grew 19.4% year-over-year, with adjusted EPS up 5.2%. Guidance for 2025 was updated, reflecting lower balloon pump demand and improved tariff outlook.
Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 28, 2025.
Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details
WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m....
First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients
The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting Stents The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting Stents